Keller, BenjaminMestre-Pintó, Juan IgnacioÁlvaro-Bartolomé, MaríaMartínez-Sanvisens, DianaFarré Albaladejo, MagíGarcía-Fuster, M. JuliaGarcía Sevilla, JesúsTorrens, MartaThe NEURODEP Group2018-11-142018-11-142017Keller B, Mestre-Pinto JI, Álvaro-Bartolomé M, Martinez-Sanvisens D, Farre M, García-Fuster MJ. Et al. A biomarker to differentiate between primary and cocaine-induced major depression in cocaine use disorder: the role of platelet IRAS/Nischarin (I1-Imidazoline Receptor). Front Psychiatry. 2017 Dec 1;8:258. DOI: 10.3389/fpsyt.2017.002581664-0640http://hdl.handle.net/10230/35746The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD (n = 16) or CUD-induced MDD (n = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls (n = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD- comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology.application/pdfengcopyright © 2017 Keller, Mestre-Pinto, Álvaro-Bartolomé, Martinez-Sanvisens, Farre, García-Fuster, García-Sevilla and Torrens. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.AntidepressiusCocaïna -- Efectes fisiològicsMarcadors bioquímicsinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.3389/fpsyt.2017.00258IRAS/nischarinAcute tryptophan depletionAntidepressant drugsCocaine use disorderCocaine-induced depressionMajor depressive disorderPlatelet biomarkerinfo:eu-repo/semantics/openAccess